MAPT and chronic kidney disease: Both groups presented levels of CSF Aβ42/40 (Figure 2E, p = 0.2715), t-tau (Figure 2F, p = 0.7404), p-tau (Figure 2G, p = 0.9412), and NfL (Figure 2H, p = 0.2869) in the same magnitude, comparing participants with or without CKD.